BioCentury
ARTICLE | Distillery Therapeutics

Cardiovascular

May 23, 2017 8:32 PM UTC

Patient sample and mouse studies suggest inhibiting TLR4 signaling could help treat cerebral cavernous malformation (CCM). In 188 patients with familial CCM, two SNPs on TLR4 (rs10759930 and rs10759931) were associated with high CCM lesion numbers. In a mouse model of CCM, endothelium-specific knockout of TLR4 or a TLR4 antagonist tool compound decreased CCM lesion volume in the cerebellum compared with normal expression or vehicle. Next steps could include identifying and testing inhibitors of TLR4 signaling in models of CCM.

Eisai Co. Ltd. has eritoran (E5564), a synthetic lipid A analog that blocks TLR4 activation, in Phase III testing to treat severe sepsis...

BCIQ Company Profiles

University of Pennsylvania

BCIQ Target Profiles

TLR4